Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-PNP in Healthy Adults and Adult Participants With MASLD
NCT05648214Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Aug 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of pivicasiran in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Regeneron Pharmaceuticals. Started Dec 2022; status: recruiting.
02
Drugs
pivicasiran
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT05648214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648214.